CD55 and neoplasm: Interestingly, ELISA assays revealed that administration of C-PC/CMC-CD55 in mice increased levels of interleukin (IL)-6 and tumor necrosis factor alpha (TNFα), while reducing levels of TGFβ, suggesting at least some level of immune modulation as a possible explanation for the reduction in tumor volume observed in vivo.